MedImpact's New Gambit to Tame Soaring GLP-1 Drug Costs

SAN DIEGO, CA – March 24, 2026 – MedImpact, the nation’s largest independent pharmacy benefits company, is launching a bold new strategy aimed at one of the biggest challenges in healthcare today: the skyrocketing cost of GLP-1 weight-loss medications. The company announced two new solutions, GLP-1 Benefit 360 and GLP-1 Direct Fund, designed to provide employers with predictable pricing while improving patient access and long-term health outcomes.

This move comes as employers and health plans grapple with the immense financial pressure from drugs like Wegovy and Zepbound. With the market for GLP-1 agonists projected to surge past $55 billion by the early 2030s, and annual costs per patient often exceeding $10,000, plan sponsors are desperately seeking sustainable ways to offer these popular and effective treatments without breaking their budgets. MedImpact’s approach aims to tackle not just the price tag, but also the high rate at which patients stop taking the drugs.

A Two-Pronged Strategy for Cost and Care

MedImpact is rolling out a dual approach to give health plans flexibility in how they manage GLP-1 benefits. The two solutions cater to different employer philosophies on coverage and cost-sharing.

The flagship offering, GLP-1 Benefit 360, is structured as a fully covered benefit but with a critical twist: price predictability. MedImpact states that both plan and member spending will be capped, providing a level of financial certainty that is largely absent in the current market. This model integrates all claims within the pharmacy benefit manager (PBM) system, creating a streamlined process that avoids the complexities of separate cash-pay or compounded drug programs.

For plans seeking an alternative to a traditional covered benefit, MedImpact introduced the GLP-1 Direct Fund. This innovative model allows a plan sponsor to contribute a fixed dollar amount toward direct-to-consumer (DTC) pricing options for its members. This approach shields the plan from unpredictable cost spikes while still helping employees afford the medication at a lower out-of-pocket price than typical cash options. It represents a significant departure from conventional benefit design, offering a managed, employer-subsidized pathway outside of the standard formulary.

Disrupting the Pharmacy Supply Chain

At the core of MedImpact's strategy is a direct challenge to the notoriously complex and expensive pharmaceutical supply chain. The company claims its approach is designed to bypass the traditional high-cost models that have drawn criticism for their lack of transparency and inflated prices.

“The legacy drug supply chain is unnecessarily complex and expensive and, with our GLP-1 and our unbranded biosimilar solutions, we’re taking on the status quo,” said Arpit Patel, MedImpact Senior Vice President of Trade Relations and Supply Chain, in the company's announcement. “We are reimagining the supply chain to deliver lower prices, greater access, and the advanced clinical support that employers and employees deserve.”

This strategy mirrors the company’s previous efforts with unbranded biosimilars, where it sought more direct procurement channels to lower costs. By creating pathways that may circumvent the intricate system of rebates and intermediaries, MedImpact aims to deliver a more straightforward and lower net cost to its clients. This move positions the independent PBM as a disruptor against its larger competitors—such as Express Scripts, CVS Caremark, and OptumRx—who have historically relied heavily on the rebate system to manage drug costs.

Beyond the Pill: A Focus on Sustainable Outcomes

Perhaps the most critical component of MedImpact's new offering is its deep integration of clinical and lifestyle support. A major weakness of GLP-1 therapy has been poor adherence, with studies showing that more than half of patients discontinue treatment within a year due to side effects, cost, or a perceived lack of progress. This often leads to weight regain, undermining the initial investment and health benefits.

To combat this, GLP-1 Benefit 360 includes access to MedImpact’s MedEmpower Fuel™ mobile app and its GLP-1 Healthy Weight program at no additional cost. This program pairs each member with a specially trained registered dietitian who can provide personalized nutrition counseling, help manage side effects like nausea, and offer motivational support. Clinical evidence strongly suggests that combining GLP-1 medication with such intensive behavioral interventions leads to significantly greater weight loss and, more importantly, improves the chances of long-term maintenance.

By bundling comprehensive support into the benefit, MedImpact is betting that improving patient outcomes is the key to justifying the high cost of the drugs. This holistic approach aims to ensure that when a plan does invest in GLP-1 therapy, the investment yields sustainable results for the member, potentially reducing future healthcare costs associated with obesity-related comorbidities.

A Shifting Landscape for Obesity Care Benefits

MedImpact’s launch enters a fiercely competitive and rapidly evolving market. Other major PBMs are also deploying strategies to manage GLP-1 spending. Express Scripts, for instance, has programs that cap member copays and require enrollment in virtual health coaching to maintain coverage. Similarly, CVS Caremark has reported significant savings for clients who adopt its integrated weight management program, which also relies on dietitian support.

What sets MedImpact's strategy apart is its direct assault on supply chain pricing combined with a fully integrated, no-extra-cost support system. This combination directly addresses the two primary pain points for employers: unpredictable costs and questionable long-term value. For the nearly 75% of employers who do not currently cover these drugs for weight loss, solutions that promise both budget control and tangible health improvements could prove to be a compelling reason to reconsider their stance.

As patient demand continues to surge, employers are caught between a desire to support employee health and the stark reality of their pharmacy budgets. The industry is now watching to see if this new model can deliver on its promise of making revolutionary obesity treatments both affordable for payers and sustainably effective for patients.